Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.46 |
| ▸ | NSD2 | O96028 | 1/20 | 0.43 |
| ▸ | WDR5 | P61964 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 6/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.41 |
| ▸ | MEN1 | O00255 | 5/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | THRB | P10828 | 2/20 | 0.41 |
| ▸ | RECQL | P46063 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18373058 | 0.90 | ALOX5 (0.48) | ALOX5NSD2WDR5MAPTKMT2A | |
| SCHEMBL18602956 | 0.83 | NSD2 (0.51) | NSD2MAPTKMT2ALMNACYP3A4 | |
| SCHEMBL11907125 | 0.82 | ALOX5 (0.41) | ALOX5NSD2WDR5MAPTKMT2A | |
| SCHEMBL15086697 | 0.81 | NSD2 (0.50) | NSD2MAPTKMT2AMEN1LMNA | |
| SCHEMBL114286 | 0.81 | PTGES (0.45) | ALOX5MAPTKMT2AMEN1LMNA | |
| SCHEMBL6128434 | 0.80 | CYP1A2 (0.40) | ALOX5MAPTKMT2ALMNACYP3A4 | |
| SCHEMBL13083064 | 0.79 | NSD2 (0.48) | NSD2WDR5MAPTKMT2ALMNA | |
| SCHEMBL13064206 | 0.79 | NSD2 (0.48) | NSD2MAPTKMT2ALMNACYP3A4 | |
| SCHEMBL114127 | 0.79 | NSD2 (0.48) | NSD2MAPTKMT2AMEN1LMNA | |
| SCHEMBL13397787 | 0.78 | NSD2 (0.47) | NSD2WDR5MAPTKMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2023-04-20 | — | — | US | disclosed |
| CN-115448849-B | Preparation method of 2-benzyloxy-3-dibenzylamino-5-fluoro-6-methylbenzoic acid phenyl ester | 苏州富士莱医药股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| CN-115448849-A | Preparation method of 2-benzyloxy-3-dibenzylamino-5-fluoro-6-methyl benzoate | 苏州富士莱医药股份有限公司 | 2022-12-09 | — | — | CN | disclosed |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2021-04-29 | — | — | US | disclosed |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-03-14 | — | — | US | disclosed |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2019-01-03 | — | — | US | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-2424834-B1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THEREOF | HARVARD COLLEGE (US) | 2018-07-11 | — | — | EP | disclosed |
| EP-3000805-B1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-18 | — | — | EP | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELOWS OF HARVARD COLLEGE (US) | 2012-05-10 | — | — | US | disclosed |
| EP-2424834-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | President and Fellows of Harvard College (US) | 2012-03-07 | — | — | EP | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| WO-2010129057-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
| WO-2010126607-A2 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-11-04 | — | — | WO | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115818-A1 | SYNTHESIS OF TETRACYCLINES AND INTERMEDIATES THERETO | TET1, TET3, TYMS | ALOX5 606/4885NSD2 4709/4885WDR5 2722/4885 |
| US-20200055813-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ALOX5 3940/4885NSD2 4380/4885WDR5 1528/4885 |
| US-20100105671-A1 | C7-fluoro substituted tetracycline compounds | F7, TUBA1C, TUBA4A | ALOX5 3940/4885NSD2 4380/4885WDR5 1528/4885 |
| US-20110269714-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | ALOX5 4429/4885NSD2 3471/4885WDR5 1167/4885 |
| US-20190002398-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ALOX5 3940/4885NSD2 4380/4885WDR5 1528/4885 |
| US-20230122651-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ALOX5 3940/4885NSD2 4380/4885WDR5 1528/4885 |
| US-20190077803-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1C, TUBA1A | ALOX5 4070/4885NSD2 3715/4885WDR5 1685/4885 |
| US-20210122709-A1 | C7-FLUORO SUBSTITUTED TETRACYCLINE COMPOUNDS | F7, TUBA1C, TUBA4A | ALOX5 3940/4885NSD2 4380/4885WDR5 1528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.